Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 7/20 | 0.58 |
| ▸ | LTA4H | P09960 | 1/20 | 0.58 |
| ▸ | GPR34 | Q9UPC5 | 2/20 | 0.54 |
| ▸ | MME | P08473 | 1/20 | 0.52 |
| ▸ | ACE | P12821 | 1/20 | 0.52 |
| ▸ | CPA1 | P15085 | 1/20 | 0.52 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.52 |
| ▸ | BRD4 | O60885 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | MMP9 | P14780 | 1/20 | 0.51 |
| ▸ | MMP8 | P22894 | 1/20 | 0.51 |
| ▸ | YAP1 | P46937 | 4/20 | 0.50 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.49 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7708717 | 0.85 | PPARG (0.47) | PPARGLTA4HGPR34MMEACE | |
| SCHEMBL3499757 | 0.83 | LTA4H (0.65) | PPARGLTA4HGPR34MMEACE | |
| SCHEMBL3499760 | 0.83 | LTA4H (0.65) | PPARGLTA4HGPR34MMEACE | |
| SCHEMBL13110180 | 0.83 | LTA4H (0.65) | PPARGLTA4HGPR34MMEACE | |
| Hydrochloric Acid SCHEMBL29693844 | 0.82 | LTA4H (0.64) | PPARGLTA4HGPR34MMEACE | |
| SCHEMBL6662616 | 0.81 | PPARG (0.60) | PPARGLTA4HGPR34GAARAB9A | |
| SCHEMBL25453218 | 0.81 | LTA4H (0.62) | PPARGLTA4HGPR34MMEACE | |
| SCHEMBL12379283 | 0.81 | LTA4H (0.62) | PPARGLTA4HGPR34MMEACE | |
| SCHEMBL16552342 | 0.81 | PPARG (0.69) | PPARGLTA4HGPR34MMEACE | |
| SCHEMBL2786362 | 0.80 | YAP1 (0.56) | PPARGLTA4HYAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110300129-A1 | SYSTEMS AND METHODS FOR ENHANCING VACCINE EFFICACY | UNIVERSITY OF ROCHESTER (US) | 2011-12-08 | — | — | US | disclosed |
| WO-2010075037-A1 | SYSTEMS AND METHODS FOR ENHANCING VACCINE EFFICACY | UNIVERSITY OF ROCHESTER (US) | 2010-07-01 | — | — | WO | disclosed |
| US-6294580-B1 | FOR THERAPY AND PROPHYLAXIS OF TYPE II OR NON-INSULIN DEPENDENT DIABETES MELLITUS, HYPERGLYCAEMIA, DYSLIPIDEMIA, TYPE II DIABETES, TYPE I DIABETES, HYPERTRIGLYCERIDEMIA, SYNDROME X, INSULIN RESISTANCE, HEART FAILURE | GLAXO WELLCOME INC. | 2001-09-25 | — | — | US | disclosed |
| EP-0888317-B1 | SUBSTITUTED 4-HYDROXY-PHENYLALCANOIC ACID DERIVATIVES WITH AGONIST ACTIVITY TO PPAR-GAMMA | GLAXO GROUP LTD (GB) | 2001-09-12 | — | — | EP | disclosed |
| EP-0888317-A1 | SUBSTITUTED 4-HYDROXY-PHENYLALCANOIC ACID DERIVATIVES WITH AGONIST ACTIVITY TO PPAR-GAMMA | GLAXO GROUP LIMITED (GB) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997031907-A1 | SUBSTITUTED 4-HYDROXY-PHENYLALCANOIC ACID DERIVATIVES WITH AGONIST ACTIVITY TO PPAR-GAMMA | GLAXO GROUP LIMITED (GB) | 1997-09-04 | — | — | WO | disclosed |